Comparing the current results to its competitors, Alector Inc reported Revenue decrease in the 1 quarter 2026 year on year by -71.53 %, despite the revenue increase by the most of its competitors of 22.63 %, recorded in the same quarter.
Alector Inc 's Comment on Competition and Industry Peers
The competitive landscape includes companies developing blood-brain barrier transport technologies targeting the transferrin receptor (TfR), which pose a competitive risk to the ABC platform. Key competitive factors are efficacy, safety profile, method of administration, cost, time to market, promotional activity, and intellectual property protection. Orphan drug exclusivity can prevent approval of competing products for seven years if a competitor obtains approval first for the same product and indication, as defined by the FDA. Orphan drug status in the European Union has similar but not identical requirements and benefits. In 2021, litigation challenged the FDA's interpretation of the scope of orphan drug exclusivity.
October 21, 2025
Alector s Advancements and Challenges in Neurodegenerative Therapies: A Comprehensive Update SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 Alector, Inc. (Nasdaq: ALEC), a prominent clinical-stage biotechnology firm, continues to navigate the complex landscape of neurodegenerative disease treatment. The company, which specializes in creating therapies aimed at mitigating neurodegeneration s devastating effects, has recently unveiled significant findings from its advanced clinical trials, offering a nuanced view of both progress and hurdles. Results from the Latozinemab Phase 3 TrialAlector has announced the much-anticipated results from the Phase 3 INFRONT-3 clinical trial, focused on evaluating latozinemab ...
February 8, 2024
In a significant development for the field of Alzheimer s disease research, Alector recently announced the dosing of its first patient in the PROGRESS-AD Phase 2 clinical trial. Conducted in partnership with GSK, this innovative trial aims to evaluate the efficacy and safety of AL101/GSK4527226 in patients with early-stage Alzheimer s disease. With an anticipated global enrollment of approximately 282 patients, the trial holds promise for potential breakthroughs in the treatment of this devastating neurodegenerative disorder.The Progress of the PROGRESS-AD Trial:The initiation of the PROGRESS-AD Phase 2 clinical trial signifies a decisive step towards addressing the urgent need for effective Alzheimer s dise...
Calidi Biotherapeutics Inc's business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.
Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.
Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
Sources:
Alector Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Alector Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
